Document is current
Any future updates will be listed below
-
Authors
Kurma, Keerthi
Bardol, Thomas
Mollevi, Caroline
Eslami-S, Zahra
Garima, Françoise
Alexandre, Marie
Bobrie, Angélique
Lossaint, Gerald
Massemin, Blandine
D’Hondt, Véronique
Guiu, Séverine
Cayrefourcq, Laure
Jacot, William
Alix-Panabières, Catherine
- License Information
-
More Information
Article History
Received: 6 February 2026
Accepted: 4 April 2026
First Online: 18 April 2026
Declarations
:
: All patients provided their written informed consent and were prospectively included in the ethics committee-approved (CPP Ouest 4) ALCINA 2 study.
: Catherine Alix‐Panabières is one of the patent holders (US Patent Number 16,093,934) for detecting and/or characterizing circulating tumor cells. She received an honorarium from Menarini©. William Jacot is on the Astra Zeneca, Eisai, BMS, Lilly France, Daiichi Sankyo, MSD, Novartis, Pfizer, Roche, and Seagen advisory boards and received honoraria or payment from Astra Zeneca, Eisai, BMS, Lilly France, Daiichi Sankyo, MSD, Novartis, Pfizer, Roche and Seagen. William Jacot also received meeting travel support from Astra Zeneca, Novartis, Chugai Pharma, Pfizer, Eisai, Pierre Fabre, Glaxo SmithKline, Roche, Lilly France, Sanofi, and Aventis. The remaining authors declare no conflict of interest.
